Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 IN PLASTIC CONTAINER versus TRAVASOL 3 5 SULFITE FREE W ELECTROLYTES IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 IN PLASTIC CONTAINER versus TRAVASOL 3 5 SULFITE FREE W ELECTROLYTES IN PLASTIC CONTAINER.
AMINOSYN 3.5% IN PLASTIC CONTAINER vs TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosin 3.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, maintaining nitrogen balance, and supporting tissue repair and growth in patients unable to tolerate oral/enteral nutrition.
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES is a parenteral nutrition solution providing amino acids, electrolytes, and calories (as dextrose). Amino acids are used for protein synthesis, and electrolytes maintain acid-base balance and osmotic pressure.
Intravenous infusion of 500 mL to 1 L daily, providing 3.5% amino acids (31.5 g protein per liter). Administer at a rate not exceeding 100 mL/hour initially, adjusted based on metabolic tolerance.
Intravenous infusion of 3.5% amino acid solution at a rate of 1-2 mL/kg/hour, adjusted to meet metabolic needs. Typical adult daily dose: 0.8-1.5 g amino acids/kg/day, equivalent to 23-43 mL/kg/day of TRAVASOL 3.5%.
None Documented
None Documented
The terminal elimination half-life of infused amino acids is approximately 18-24 minutes, reflecting rapid clearance from plasma into tissues for protein synthesis.
Not applicable as a fixed half-life; amino acids have rapid plasma clearance (t1/2 of 10-30 minutes for individual amino acids). Clinical context: Continuous infusion maintains steady state.
Amino acids are metabolized to urea and carbon dioxide; urea is excreted renally (90%) and to a lesser extent via sweat and feces (<10%).
Renal: >95% of infused amino acids and electrolytes are excreted unchanged or as metabolites. Biliary/fecal: <5%.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution